Literature DB >> 22948875

No recurrence of Pneumocystis jirovecii Pneumonia after solid organ transplantation regardless of secondary prophylaxis.

Tark Kim1, Heungsup Sung, Yu-Mi Lee, Hyo-Lim Hong, Sung-Han Kim, Sang-Ho Choi, Jun Hee Woo, Yang Soo Kim, Sang-Oh Lee.   

Abstract

There are no data on the efficacy of secondary prophylaxis against Pneumocystis pneumonia after solid organ transplantation. Therefore, we investigated the rate of recurrence of Pneumocystis pneumonia after solid organ transplantation in a retrospective cohort study. Between 2005 and 2011, a total of 41 recipients recovered from Pneumocystis pneumonia. Of these, 22 (53.7%) received secondary prophylaxis. None of the 41 recipients experienced recurrence of Pneumocystis pneumonia during the follow-up, regardless of secondary prophylaxis.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22948875      PMCID： PMC3486611          DOI： 10.1128/AAC.00998-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients.

Authors:  Frank Eitner; Ingeborg A Hauser; Olaf Rettkowski; Thomas Rath; Kai Lopau; Rainer U Pliquett; Roman Fiedler; Markus Guba; Ralf-Dieter Hilgers; Jürgen Floege; Michael Fischereder
Journal:  Nephrol Dial Transplant       Date:  2010-11-11       Impact factor: 5.992

2.  Pneumocystis pneumonia in solid organ transplant recipients.

Authors:  S I Martin; J A Fishman
Journal:  Am J Transplant       Date:  2009-12       Impact factor: 8.086

Review 3.  Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.

Authors:  J E Kaplan; D Hanson; M S Dworkin; T Frederick; J Bertolli; M L Lindegren; S Holmberg; J L Jones
Journal:  Clin Infect Dis       Date:  2000-04       Impact factor: 9.079

Review 4.  Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome.

Authors:  Kent A Sepkowitz
Journal:  Clin Infect Dis       Date:  2002-03-21       Impact factor: 9.079

5.  Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression.

Authors:  V Lufft; V Kliem; M Behrend; R Pichlmayr; K M Koch; R Brunkhorst
Journal:  Transplantation       Date:  1996-08-15       Impact factor: 4.939

6.  Mycophenolate mofetil may protect against Pneumocystis carinii pneumonia in renal transplanted patients.

Authors:  Luiz Sergio Azevedo; Maria Cristina R Castro; Flavio J Paula; Luiz Estevam Ianhez; Elias David-Neto
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2005-07-12       Impact factor: 1.846

7.  A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.

Authors:  J C Lopez Bernaldo de Quiros; J M Miro; J M Peña; D Podzamczer; J C Alberdi; E Martínez; J Cosin; X Claramonte; J Gonzalez; P Domingo; J L Casado; E Ribera
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

8.  Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?

Authors:  S M Gordon; S P LaRosa; S Kalmadi; A C Arroliga; R K Avery; L Truesdell-LaRosa; D L Longworth
Journal:  Clin Infect Dis       Date:  1999-02       Impact factor: 9.079

9.  Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Jonathan E Kaplan; Constance Benson; King K Holmes; John T Brooks; Alice Pau; Henry Masur
Journal:  MMWR Recomm Rep       Date:  2009-04-10

10.  A multicenter randomized double-blind placebo-controlled trial of adjunctive corticosteroids in the treatment of Pneumocystis carinii pneumonia complicating the acquired immune deficiency syndrome.

Authors:  S Walmsley; C Levinton; J Brunton; D Muradali; D Rappaport; M Bast; D Spence; I Salit
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-04-01
View more
  1 in total

1.  Factors Associated with Pneumocystis jirovecii Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study.

Authors:  Shin-Ichiro Ohmura; Yoichiro Homma; Takayuki Masui; Toshiaki Miyamoto
Journal:  Intern Med       Date:  2021-09-11       Impact factor: 1.282
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.